Ideaya Biosciences IncIDYA
Price$37.81Intrinsic value$88.57134% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $218.7M+3,024.4% YoYTTM through 30 Jun 2026
Net Income -$175MTTM through 30 Jun 2026
Free Cash Flow -$113.9MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin-97.9%
Operating Margin-72.8%
Net Margin-52.0%

Returns

-11.1%ROE
-10.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio11.34x
Net Debt-$639.4Mnet cash position
Cash & Equivalents$272.6M

Quality Metrics

Altman Z-Score20.07
Piotroski F-Score2 / 9
FCF Margin-52.1%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $218.7M
Diluted EPS-$1.92TTM
'20'21'22'23'24'25
FY2025: $-1.28

Dividend

No dividend

Capital Allocation

Capex Intensity1.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.